Corona Remedies Ltd

Sepia Investments Ltd, Anchor Partners, and Sage Investment Trust have collectively sold a significant number of equity shares in Corona Remedies Limited. Specifically, Sepia Investments sold 4,328,943 shares, Anchor Partners sold 161,861 shares, and Sage Investment Trust sold 90,087 shares. This disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The transactions involve the sale of equity shares of a company listed on both BSE and NSE.

Sepia Investments Limited, Anchor Partners, and Sage Investment Trust have collectively sold 4,581,791 equity shares, representing approximately 7.5% of the total share capital, in Corona Remedies Limited. The sale was disclosed under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. Prior to the sale, these entities held a combined 20.91% stake in the company, which is listed on both BSE and NSE. The disclosure details the number of shares sold and the percentage of total share capital they represent.

Invesco Mutual Fund, through various schemes including Invesco India Consumption Fund and Invesco India Smalleap Fund, has disclosed its aggregate holding in Corona Remedies Limited. As of June 17, 2026, their total shareholding stands at 5.0562% of the company's paid-up share capital. This disclosure is made in compliance with Regulation 29(1) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The acquisition involved an increase of 0.4726%, bringing their total shares to 30,92,372.

Invesco Mutual Fund, through various schemes including Invesco India Consumption Fund and Invesco India Smalleap Fund, has increased its shareholding in Corona Remedies Limited. The aggregate holding now stands at 5.0562% of the company's paid-up share capital as of June 17, 2026. This disclosure is made in compliance with SEBI's Substantial Acquisition of Shares & Takeovers Regulations, 2011. The acquisition involved an increase of 0.4726% in voting rights, bringing the total to 5.0562%. The total equity share capital of Corona Remedies Limited remains Rs. 61,16,00,880/-.

Corona Remedies Ltd has announced its 22nd Annual General Meeting (AGM) scheduled for July 9, 2026, to be held via video conferencing. The company is also distributing its Annual Report for the Financial Year 2025-26. Shareholders who have not registered their email IDs will receive a letter with a weblink to access the report and AGM notice. The Board of Directors has recommended a dividend of ₹10 per equity share, subject to member approval at the AGM. Shareholders are urged to update their KYC details for electronic dividend payments and to facilitate digital communication.

Corona Remedies Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, as mandated by SEBI regulations. The report, which forms part of the company's Annual Report, details its corporate identity, operational locations, employee statistics, and market reach. The company reported 100% of its turnover from the manufacturing of pharmaceutical products and serves a diverse customer base including pharmacies, hospitals, and other consumers. Exports contributed approximately 4.06% to the total turnover.

Corona Remedies Ltd has announced its 22nd Annual General Meeting (AGM) will be held on Thursday, July 09, 2026, at 11:00 a.m. via Video Conferencing (VC) / Other Audio Visual Means (OAVM). The company will submit its Annual Report for FY 2025-26 along with the AGM notice. Thursday, July 02, 2026, has been set as the cut-off date for determining voting rights for the AGM. The filing also highlighted strong financial performance for FY 2025-26, with India business revenue growing 17.18% against an IPM growth of 8.59%. Key financial highlights include Revenue from Operations of ₹1,403.18 Crores, Operating Profit of ₹293.44 Crores, and PAT of ₹199.42 Crores.

Corona Remedies Ltd has released its Annual Report for FY 2025-26, coinciding with the notice for its 22nd Annual General Meeting (AGM) scheduled for July 9, 2026. The report highlights a landmark year with India business revenue growth of 17.18%, significantly outperforming the IPM growth of 8.59%. Key financial metrics include Revenue from Operations at ₹1,403.18 Crores, Operating Profit at ₹293.44 Crores, and PAT at ₹199.42 Crores. The company also announced July 2, 2026, as the cut-off date for electronic voting and AGM attendance. The report details strategic expansions, new product launches, and strengthening of its specialty-led field structure.

CORONA Remedies Limited has received EU-GMP Compliance Certification for its Hormone manufacturing facility and renewed EU-GMP approval for its Oral Solid Dosage (OSD) manufacturing facility at Bhayla, Ahmedabad. These accreditations follow an EUDRA GMP inspection conducted in April 2026. The company states that these milestones strengthen its global manufacturing and quality credentials, reaffirming its commitment to world-class quality systems and international standards. Mr. Viral Sitwala, Executive Director, highlighted that this reflects their commitment to quality and aims to serve both Indian and global regulated/semi-regulated markets, particularly expanding their Hormone portfolio internationally.

Corona Remedies Ltd has appointed M/s. Shah & Shah Associates, Chartered Accountants, as the Internal Auditor of the company for the financial year 2026-27. This decision was made based on the recommendation of the Audit Committee and approved by the Board of Directors during their meeting held on May 11, 2026.